Munich — Bayer has struck an $875m deal to acquire British women’s health biotech Kandy Therapeutics, bolstering its pharmaceuticals division before patents expire on some key products.
Kandy’s drug NT-814 is expected to start a final-stage clinical trial next year and could generate peak sales of €1bn globally, Bayer said in a statement on Tuesday. Bayer rose as much as 1.8% in Frankfurt. Last August, Bayer’s pharma unit agreed to pay as much as $600m to buy the remainder of cell therapy biotech BlueRock Therapeutics. At the time, Stefan Oelrich, Bayer’s head of pharma, said that the best value-creating deals in the industry in recent years have targeted early-stage companies with products that wound up becoming blockbusters.
مصر أحدث الأخبار, مصر عناوين
Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.
Fake news! Zweli Mkhize does not own a PPE manufacturing companySA's health ministry rubbished claims on Monday that Dr Zweli Mkhize - at the forefront of the country's battle against the coronavirus pandemic - owned a company that manufactured personal protective equipment (PPE).
مصدر: TimesLIVE - 🏆 28. / 59 اقرأ أكثر »
Fake news! Zweli Mkhize does not own a PPE manufacturing companySA's health ministry rubbished claims on Monday that Dr Zweli Mkhize — at the forefront of the country's battle against the coronavirus pandemic — owned a company that manufactured personal protective equipment (PPE).
مصدر: SowetanLIVE - 🏆 13. / 63 اقرأ أكثر »
مصدر: eNCA - 🏆 49. / 51 اقرأ أكثر »